KR20160113664A - 염증성 빈혈 치료에 사용되는 파리칼시톨의 용도 - Google Patents

염증성 빈혈 치료에 사용되는 파리칼시톨의 용도 Download PDF

Info

Publication number
KR20160113664A
KR20160113664A KR1020167023202A KR20167023202A KR20160113664A KR 20160113664 A KR20160113664 A KR 20160113664A KR 1020167023202 A KR1020167023202 A KR 1020167023202A KR 20167023202 A KR20167023202 A KR 20167023202A KR 20160113664 A KR20160113664 A KR 20160113664A
Authority
KR
South Korea
Prior art keywords
esa
paricalcitol
patients
levels
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167023202A
Other languages
English (en)
Korean (ko)
Inventor
미구엘 지오반니 유리올 리베라
Original Assignee
미구엘 지오반니 유리올 리베라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미구엘 지오반니 유리올 리베라 filed Critical 미구엘 지오반니 유리올 리베라
Publication of KR20160113664A publication Critical patent/KR20160113664A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/814—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167023202A 2014-02-11 2015-01-16 염증성 빈혈 치료에 사용되는 파리칼시톨의 용도 Ceased KR20160113664A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201430177 2014-02-11
ES201430177A ES2472040B1 (es) 2014-02-11 2014-02-11 Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PCT/EP2015/050817 WO2015121022A1 (en) 2014-02-11 2015-01-16 Use of paricalcitol in the treatment of inflammatory anaemia

Publications (1)

Publication Number Publication Date
KR20160113664A true KR20160113664A (ko) 2016-09-30

Family

ID=51205045

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167023202A Ceased KR20160113664A (ko) 2014-02-11 2015-01-16 염증성 빈혈 치료에 사용되는 파리칼시톨의 용도

Country Status (16)

Country Link
US (1) US11464791B2 (enExample)
EP (1) EP3104872B1 (enExample)
JP (1) JP2017512753A (enExample)
KR (1) KR20160113664A (enExample)
CN (1) CN106061498B (enExample)
AR (1) AR099330A1 (enExample)
AU (1) AU2015217956B2 (enExample)
CA (1) CA2938057A1 (enExample)
DK (1) DK3104872T3 (enExample)
ES (2) ES2472040B1 (enExample)
IL (1) IL247207B (enExample)
MX (1) MX365096B (enExample)
PT (1) PT3104872T (enExample)
RU (1) RU2016131412A (enExample)
UY (1) UY35989A (enExample)
WO (1) WO2015121022A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030665A1 (ko) * 2020-08-05 2022-02-10 경상대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062620A2 (en) * 2003-01-13 2004-07-29 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
CA2563874A1 (en) * 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Erythropoietin protein variants
CN101610782A (zh) * 2007-01-10 2009-12-23 爱迪生药物公司 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
CN102772364B (zh) * 2011-05-13 2015-12-02 重庆华邦制药有限公司 帕立骨化醇的脂肪乳及其制剂和制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022030665A1 (ko) * 2020-08-05 2022-02-10 경상대학교병원 조영제-유발 신독성 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
ES2472040R1 (es) 2014-09-18
IL247207B (en) 2020-02-27
US11464791B2 (en) 2022-10-11
AU2015217956B2 (en) 2019-04-04
ES2728158T3 (es) 2019-10-22
US20160367571A1 (en) 2016-12-22
ES2472040B1 (es) 2015-07-01
RU2016131412A (ru) 2018-03-15
CN106061498A (zh) 2016-10-26
MX365096B (es) 2019-05-22
JP2017512753A (ja) 2017-05-25
CA2938057A1 (en) 2015-08-20
DK3104872T3 (da) 2019-06-17
UY35989A (es) 2015-03-27
ES2472040A2 (es) 2014-06-27
CN106061498B (zh) 2019-12-06
AR099330A1 (es) 2016-07-13
IL247207A0 (en) 2016-09-29
PT3104872T (pt) 2019-06-11
MX2016010104A (es) 2017-01-06
WO2015121022A1 (en) 2015-08-20
EP3104872A1 (en) 2016-12-21
AU2015217956A1 (en) 2016-08-25
EP3104872B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
Prats et al. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study
Maruyama et al. Ferric citrate decreases fibroblast growth factor 23 and improves erythropoietin responsiveness in hemodialysis patients
Malberti Hyperphosphataemia: treatment options
Charytan et al. Cardiorenal syndrome and the role of the bone-mineral axis and anemia
Iguchi et al. Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency
Tsukamoto et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism
Nair et al. A randomized study of a single dose of intramuscular cholecalciferol in critically ill adults
US8329677B2 (en) Method of treating and preventing secondary hyperparathyroidism
Gharekhani et al. Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients
Beer et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
JP2012527424A (ja) イネカルシトールの新しい治療的使用
Lilien et al. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis
Sethi et al. Myelofibrosis-induced erythropoietin-resistant anemia due to severe refractory hyperparathyroidism
ABDUL GAFOR et al. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism
Johnson et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial
US11464791B2 (en) Use of paricalcitol in the treatment of inflammatory anaemia
Yasin et al. Hyporesponsiveness to Erythropoietin-Stimulating Agents: Possible Solutions
Rahman et al. Mycophenolate mofetil versus cyclosporine in children with frequent relapse nephrotic syndrome
Rodelo-Haad et al. Iron repletion and FGF23 regulation. A potentially dangerous combination
Behairy et al. Effect of oral vitamin C on serum hepcidin level, iron status and inflammation among hemodialysis patients with functional iron deficiency anaemia
Blindar et al. Peculiarities of iron metabolism in patients with breast cancer before adjuvant chemotherapy
Alam et al. Anemia risk is increased in individuals who have a vitamin d deficiency
Goldfarb-Rumyantzev et al. Chronic Kidney Disease
Bashardoust et al. Treatment effect of ergocalciferol on bone metabolism indexes and parathyroid hormone in hemodialysis patients
Abu-Hamdan et al. Zinc tolerance test in uremia: effect of calcitriol supplementation.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160824

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191128

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20191128

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200116

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200511

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200116

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I